Open for inclusion

A PHASE IA/IB OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF RO7198457 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS

Cancer type: Multiple diagnosis

Phase: I

Principal Investigator: Yachnin Jeffrey

Country: SE

Keywords: Sweden, Stockholm, GO39733

Status: Open for inclusion

Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT03289962?term=GO39733&rank=1